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ARTICLE
A Potential Contributory Role for Ciliary Dysfunction
in the 16p11.2 600 kb BP4-BP5 Pathology
Eugenia Migliavacca,1,2,13 Christelle Golzio,3,13 Katrin Ma¨nnik,1,4,13 Ian Blumenthal,5 Edwin C. Oh,3
Louise Harewood,1,15 Jack A. Kosmicki,6,7 Maria Nicla Loviglio,1 Giuliana Giannuzzi,1 Loyse Hippolyte,8
Anne M. Maillard,8 Ali Abdullah Alfaiz,1,2 16p11.2 European Consortium, Mieke M. van Haelst,9
Joris Andrieux,10 James F. Gusella,5,11 Mark J. Daly,6,7 Jacques S. Beckmann,2,8,12 Se´bastien Jacquemont,8
Michael E. Talkowski,5,11 Nicholas Katsanis,3,14,* and Alexandre Reymond1,14,*
The 16p11.2 600 kb copy-number variants (CNVs) are associated with mirror phenotypes on BMI, head circumference, and brain vol-
ume and represent frequent genetic lesions in autism spectrum disorders (ASDs) and schizophrenia. Here we interrogated the transcrip-
tome of individuals carrying reciprocal 16p11.2 CNVs. Transcript perturbations correlated with clinical endophenotypes and were
enriched for genes associated with ASDs, abnormalities of head size, and ciliopathies. Ciliary gene expression was also perturbed in
orthologousmousemodels, raising the possibility that ciliary dysfunction contributes to 16p11.2 pathologies. In support of this hypoth-
esis, we found structural ciliary defects in the CA1 hippocampal region of 16p11.2 duplication mice. Moreover, by using an established
zebrafish model, we show genetic interaction between KCTD13, a key driver of the mirrored neuroanatomical phenotypes of
the 16p11.2 CNV, and ciliopathy-associated genes. Overexpression of BBS7 rescues head size and neuroanatomical defects of kctd13
morphants, whereas suppression or overexpression ofCEP290 rescues phenotypes induced by KCTD13 under- or overexpression, respec-
tively. Our data suggest that dysregulation of ciliopathy genes contributes to the clinical phenotypes of these CNVs.
Introduction
Copy number variants (CNVs) with rare population pre-
valence are major contributors to neurodevelopmental
disorders. For example, the recurrent 16p11.2 BP4-BP5
(breakpoint 4-5) 600 kb deletion (MIM: 611913; Figure 1A)
is one of the most frequent known genetic lesions in
individuals with ASD.1–3 This CNV also predisposes to
penetrant forms of obesity4–6 andmacrocephaly.6,7 A series
of mirror phenotypes is observed in carriers of the recip-
rocal duplication (MIM: 614671), who are at high risk of
being underweight and microcephalic and developing
schizophrenia (SCZ)6–8 as well as Rolandic epilepsy.9
Similarly, deletion and duplications show a mirroring
impact on brain structures implicated in reward, language,
and social cognition.10 Systematic phenotyping of dele-
tion carriers showed a 30-point decrease in IQ, language
impairment, and psychiatric co-morbidities, as well as
an increased growth velocity of head circumference (HC)
during infancy11 that recapitulates the pattern reported
in idiopathic ASD.12
Among the 32 genes perturbed directly by the 16p11.2
600 kb CNVs, suppression of kctd13 induces macrocephaly
in zebrafish embryos, whereas the reciprocal overexpres-
sion of human KCTD13 (MIM: 608947) can induce a
microcephalic phenotype with concomitant reduction of
neurogenesis. Microcephaly was further amplified upon
co-injection of either MAPK3 (MIM: 601795) or MVP
(MIM: 605088) RNAs, suggesting epistatic interactions for
this phenotype in 16p11.2 CNV carriers.13 KCTD13 was
associated recently with schizophrenia14 and maps within
a smaller 118 kb deletion that segregates with ASD in a
three-generation pedigree15 (Figure 1A). Despite these
clues and other advances,16–19 the etiopathology of these
lesions remains poorly understood. CNVs can impact
transcriptomes by modifying the levels and timing of
expression of genes localized both within the CNV20,21
and on its flanks,20,22–24 an effect that can extend over
the entire length of the affected chromosome.25 Therefore,
we undertook a transcriptome analysis of 16p11.2 deletion
and duplication carriers and asked whether reciprocal
deletion or duplication of the 16p11.2 region correlates
with cellular processes or signaling pathways that might
inform on involved pathomechanisms. We identified a
significant enrichment of expression level changes in
pathways relevant to neurodevelopment and primary
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ciliary functions. These results were confirmed in brains
from 16p11.2 CNV mouse models, in which we detected
both transcriptional dysregulation and concomitant struc-
tural ciliary defects. These results were complemented by
epistasis and rescue experiments in zebrafish embryos,
confirming the link between 16p11.2 dosage and cilia.
Material and Methods
Samples
The institutional review board of the University of Lausanne,
Switzerland, approved this study. Participants were enrolled in
the study after signing an informed consent form and being clin-
ically assessed by their respective physicians. For the data collected
through questionnaires, information was gathered retrospectively
and anonymously by physicians who had ordered comparative
genomic hybridization (CGH) analyses performed for clinical pur-
poses only. Consequently, research-based informed consent was
not required by the institutional review board of the University
of Lausanne, which granted an exemption for this part of the
data collection. Details on ascertainment and data collection
were previously published.6,11 Overall cognitive functioning was
assessed as published.11 Z scores were computed for all data using
reference populations of European descent matched for gender,
age, and geography as previously described.6
A
B
Figure 1. Expression Level Changes in 16p11.2 Deletion and Duplication LCLs
(A) Comparison of the GRCh37/hg19 genomic boundaries of the recurrent 600 kb BP4-BP5 16p11.2 deletion with that of the 118 kb
atypical deletion described in Crepel et al.15 The genes mapping within the interval are shown in blue. The low-copy repeats (LCRs)
at the rearrangement breakpoints are indicated at the bottom.
(B) Boxplot distribution of relative expression levels measured by microarrays in deletion (n ¼ 50) and duplication (n ¼ 31) carriers (red
and green, respectively) and control LCLs (n ¼ 17, blue) of the 19 ‘‘unique’’ and 3 multiple-copy genes (plus the read-through transcrip-
tion between SLX1A/1B [MIM: 615822/615823] and SULT1A3/A4 [MIM: 600641/615819]) expressed in LCLs and mapping within the
16p11.2 BP4-BP5 interval and its flanking LCRs, respectively. Note that the expression level of these transcripts, de facto positive con-
trols, is positively correlated with gene dosage.
The American Journal of Human Genetics 96, 784–796, May 7, 2015 785
We established lymphoblastoid cell lines (LCLs) from deletion
and duplication carriers as well as controls (Table S1) by transform-
ing peripheral blood mononuclear cells with EBV. In brief,
heparinized whole-blood samples of enrolled individuals were
collected and processed with Ficoll-Paque Premium (GE Health-
care Bio-Sciences AB) centrifugation according to the manufac-
turer’s protocol, after which the mononuclear cell fractions were
isolated. Mononuclear cells were incubated with an Epstein-Barr
virus suspension to enable transformation. Upon transformation,
the cells were cultured in RPMI 1640 medium (GIBCO), supple-
mented with 10% Fetal Bovine Serum (PAA, GE Healthcare) and
1% penicillin/streptomycin (GIBCO), at 37C and 5% CO2 until
a stable and exponentially growing cell line was established.
RNA Preparation
For RNA isolation, exponentially growing LCLs were harvested
and resuspended in TRIzol reagent (Ambion), after which the
manufacturer’s protocol for RNA isolation was performed. Upon
RNA isolation, RNA clean-up was performed with the RNeasy
Mini Kit (QIAGEN), including the DNase treatment step, according
to the manufacturer’s protocol. RNA quality and concentration
were determined with a NanoDrop ND-1000 spectrophotometer
(Thermo Scientific) and a 2100 Bioanalyzer platform (Agilent).
Microarray Data Analysis
For each sample, 100 ng of total RNA was processed according
to the Affymetrix GeneChip 30 IVT Express Kit manual (P/N
702646 Revision 6) and hybridized to the Affymetrix GeneChips
Human Genome U133þ PM 24 array plates (GEO platform
GPL13158). The Affymetrix GeneTitan Instrument was used for
automated array processing. Raw data were generated and ex-
tracted from the scanned images for analysis with the Affymetrix
GeneChip Command Console (AGCC) Software and Expression
Console Software packages. Data were annotated according to
the NetAffx Analysis Center. All microarrays considered in this
analysis were performed in concomitance and, based on clustering
analyses and principal component analysis, we can exclude that
the array plate is affecting our results. The Robust Multi-array
Average (RMA) approach was employed for the creation and
normalization of the summarized probe set signals. We applied a
non-specific filter to discard probe sets with low variability and
low signal: we retained 23,602 probe sets whose SD was greater
than median of SD of all probe sets and maximum signal greater
than the median of maximum signal of all probe sets. To reduce
a potential bias toward genes with multiple probe sets, for the
modular analysis, we kept only one probe set with the highest
variance per gene, for a total of 15,112 probe sets, 11,830 with
Entrez Id and 3,282 without Entrez Id.
Differential Expression Analysis
Genes (represented by 23,602 probe sets) were tested for differen-
tial expression via the moderated t-statistic as implemented in
Limma.26 We evaluated a dosage model in which CNV was
treated as a numerical variable to reflect a dosage effect, relatedness
was taken into account by providing an estimate of the within-
family correlation via the duplicateCorrelation function in
Limma, and the model was adjusted for age and gender (Model 1:
gene ~cnvþageþgender with the cnv covariate coded as 1, 0,
1 and specified within-family correlation). We exploited topGO,
DAVID GO, g:Profiler, and Thomson Reuters MetaCore and
EnrichR to assess whether the DE genes were related to specific
pathways, enriched in specific protein domains and OMIM
terms.27–29 Similarly, we used the SFARI Gene list, the union of
the genes cataloged in Girard et al.30 and Xu et al.,31,32 and the
GWAS hits for BMI33 to assess enrichment for ASD, SCZ, and
BMI genes, respectively.
Weighted Gene Co-expression Network Analysis
We used the residual matrix of gene expression corrected for relat-
edness or for relatedness, age, and gender to build co-expression
networks with the WGCNA package in R.34 A Pearson correlation
matrix between the residuals of all gene pairs was calculated and
then an adjacency matrix was defined by the soft-thresholding
approach aij ¼ corjx,xjjb with b ¼ 6, which represent an approxi-
mate scale-free topology network with the scale-free fitting index
R2 greater than 0.85. As a preprocessing step in the construction
of the network, we selected the 50% of the genes with the
highest connectivity. The blockwiseModules function was used
for network construction and module detection. Each module
was summarized by its first principal component (designated as
eigengene) and denoted by a color. Each module eigengene was
correlatedwith the age, gender, CNV, andZ scores of the anthropo-
metricmeasures, Pearson correlation and the corresponding Benja-
mini-Hochberg adjusted p value were reported for each module.
Transcriptome Profiling of Mice Models
We sequenced RNA and profiled the transcriptome from the
cortical tissue of mice harboring deletion and duplication of
the 7qF3 region of synteny conservation with 16p11.2 as
described.35 The mouse models were created at the Cold Spring
Harbor Laboratory by A. Mills and colleagues, as previously
described in Horev et al.,36 and provided by the Jackson Labora-
tories (stock numbers 013128 and 013129). Sixteen mice were
selected from two litters of an engineered line with deletion or
duplication of the mouse 16p11.2 equivalent region plus four
additional genes found in the human immediately outside of
the segmental duplication, centromeric to the CNV (Cd2bp2,
Tbc1d10b, Mylpf, Sept1). Within each litter, four mice with CNVs
were compared to four wild-type littermates (eight total wild-
type mice). The design was fully sex balanced for each genotype.
Dissection of mouse cortex was performed simultaneously for all
mice at 8 weeks of age. RNA-seq libraries were prepared and
sequenced as detailed in Blumenthal et al.35 Raw sequence data
were quality checked with fastQC and aligned with TopHat2 using
default parameters against the RefSeq transcriptome and mm10
genome (UCSC Genome Browser, accessed September 2012). All
aligned reads were analyzed with RNA-SeqQC37 to ensure unifor-
mity of alignment rate, duplication rate, evenness of coverage,
GC content, and rRNA content. Reads aligned to the ERCC
synthetic RNAs were used to check the linearity of dose response
within and between samples, to determine the abundance limits
of gene expression that could be accurately quantified in our
experiment (defined as the average abundance of the lowest
detectable ERCC transcript from all samples), and to assess the
power to detect differential expression at varying fold-changes.
Raw gene level counts were tabulated with the BEDTools suite38
against the mouse RefSeq transcriptome (accessed February
2013). Genes with read counts below our detection threshold
in any individual sample were excluded from analysis in all sam-
ples, and raw counts were normalized with the total number
of counts generated per sample prior to statistical analysis. Gene
level read counts generated by RNA-seq are over-dispersed relative
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to the Poisson; therefore, we chose the negative binomial distribu-
tion tomodel these data.39,40 Themouse cortex data were analyzed
with negative binomial generalized linear models (GLMs). The
dispersion parameter for each gene was estimated by an iterative
weighted least-squares approach for the GLM analysis. All analyses
were conducted in R with the MASS package. Differential ex-
pression analysis was performed by fitting a factorial ANOVA
with genotype and sex as the factors. We used FDR corrected
p values (Benjamini-Hochberg FDR) for thresholds of statistical
significance, though nominally significant results were retained
for exploratory analyses. We used all genes with expression
levels above our detection thresholds as the background list
for enrichment analyses (14,435 mouse genes with human ortho-
logs). The mRNA levels of Bbs4, Bbs7, and Cep290 correlated with
number of copies of theCNV, and expression of Bbs12 andCcdc28b
were modified in the cortex of deletion mice (all p < 0.10).
Primary Cilium Immunostaining
Mice were backcrossed for three generations into a C57BL/6 back-
ground; brain tissue was obtained from mice perfused with 4%
PFA. After an overnight infiltration in 30% sucrose, 50 mmfloating
frozen sections were cut with a cryostat (Leica). All staining was
performed in a 24-well plate with an antibody against ACIII (Santa
Cruz) and DAPI (Roche). Sections were placed on a glass slide and
coverslipped with mounting medium (Millipore). Image acquisi-
tion was performed on a Zeiss LSM 710 confocal microscope,
and images with a Z plane of ~20 mm were processed with Imaris
software. Cilia trace images were obtained from amaximum image
projection of each z stack. Measurements were scored blind to the
genotype and obtained from three separate sections from three
different animals per genotype. The standard error of the mean
was plotted.
Morpholino, Immunostaining, and Embryo
Manipulations
Zebrafish (Danio rerio) embryos were raised and maintained as
described.41 Splice-blocking MOs against kctd13 (50-TCTAAGGG
TACACGCCTGACCTGTA-30) and cep290 (50-TTACGGCTCGGCA
TACCTTTGATGC-30) were designed and obtained from Gene
Tools as described.13 We injected 10 ng and 6 ng of kctd13 MO
and cep290 MO, respectively, into wild-type zebrafish embryos
at the 1- to 2-cell stage. For rescue experiments, the human wild-
type mRNAs were cloned into the pCS2 vector and transcribed
in vitro with the SP6 Message Machine kit (Ambion); 100 pg of
the human wild-type mRNAs were coinjected with the MOs. Sup-
pression of endogenous message was shown by PCR amplification
of cDNA reverse transcribed from extracted total mRNA as previ-
ously described.13 Whole-mount immunostaining with HuC/D
was performed for investigating neuronal development at a
cellular level, a surrogate for the evaluation of normal neurogene-
sis.42 Anti-HuC/D (A21271, Invitrogen) is a marker for post-
mitotic neurons, i.e., cells positive for HuC and HuD (also known
as ELAVL3 and ELAVL4). Embryos were fixed in 4% PFA overnight
and stored in 100% methanol at 20C. After rehydration in PBS,
PFA-fixed embryos were washed in immunofluorescence (IF)
buffer (0.1% Tween-20 and 1% BSA in PBS 13) for 10 min at
room temperature. The embryos were incubated in the blocking
buffer (10% FBS and 1% BSA in PBS 13) for 1 hr at room temper-
ature. After two washes in IF buffer for 10 min each, embryos were
incubated in the first antibody solution, 1:500 anti-HuC/D, in
blocking solution overnight at 4C. After two washes in IF buffer
for 10 min each, embryos were incubated in the secondary anti-
body solution, 1:500 Alexa Fluor goat anti-mouse IgG (A21207,
A11001, Invitrogen), in blocking solution for 1 hr at room temper-
ature. Stained embryos were scored visually at 2 dpf and classified
as normal (bilateral), ectopic, unilateral, or absent/reduced on the
basis of the relative expression of the HuC/D marker in the fore-
brain with that of age-matched controls from the same clutch.
Measurements of the distance between the convex tip of the eye
cups as a read-out for head size was performed at 4.5 dpf as
described.13 All the experiments were repeated three times and
chi-square or Fisher exact testswereperformed todetermine the sig-
nificance of the rescue compared to overexpressants and mor-
phants.Weblindly scored~100 injected embryos for eachmeasure.
Simons Variation in Individuals Project
The 307 Simons VIP exomes were sequenced on Illumina HiSeq
2000 systems and SNPs and indels were called in a single large
batch by GATK v.2.6. Variants were called from VCF files, anno-
tated with SNPEFF, and processed to include only high-quality
alternate variants passing GATK filters. We further restricted the
number of variants by including only those that passed a series
of thresholds to reduce false positives: read depthR 10, genotype
quality R 30, phred scale likelihood > 30, and allele balance
(defined as the ratio of alternate reads to total reads) < 0.1 for ho-
mozygous reference individuals, > 0.9 for homozygous alternate
individuals, and between 0.3 and 0.7 for heterozygous individuals.
Finally, all variants with more than 1% missing genotypes were
removed from the analysis.
Results
We profiled the transcriptome of lymphoblastoid cell lines
(LCLs) of 50 deletion and 31 duplication carriers with
BP4-BP5 boundaries, as well as of 17 control individuals
(Table S1) and tested for genes associated with the 16p11.2
CNV by using a dosage effect model and moderated
t-statistics. We identified 1,527 significantly differentially
expressed (DE) probe sets (6.5% out of 23,602 analyzed
probe sets) representing 1,188 unambiguously annotated
genes (FDR% 1%; Table S2). This set includes all 22 genes
mapping within the CNV with detectable expression
in LCLs (Figures 1A and 1B; Table S3). Consistent with
published data from LCLs6,43 and adipose tissue,5 the
expression levels of these transcripts were positively corre-
lated with gene dosage (Figure 1B). Thus, in contrast to
some other genomic disorders,22,43 none of the 16p11.2
CNV genes appear subject to dosage compensation. In
agreement with previous studies reporting that CNVs also
affect the expression of nearby flanking genes,20,22–25,43
we identified neighboring normal-copy genes with sig-
nificantly modified expression (Figure S1). Within DE
genes, we observed a significant overrepresentation of
genes implicated in processes involving RNA metabolism
and expression (Table S4). The top-10 list of MetaCore
enrichments contains also five pathways involved in
developmental signaling: glucocorticoid receptor (FDR
3.99 3 105), TGF-b receptor (FDR 9.15 3 105), VEGF
(FDR 9.15 3 105), BMP (FDR 9.91 3 105), and FGFR
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signaling (FDR 1.29 3 104) (Tables S5 and S6). We also
searched for overrepresentation of Human Phenotype
Ontology and found enrichment for ‘‘abnormality
of skull size’’ (HP:0000240; Benjamini-Hochberg FDR
1.06 3 102), ‘‘abnormality of hindbrain morphology’’
(HP:0011282; FDR 5.00 3 102), ‘‘abnormality of the
metencephalon’’ (HP:0011283; FDR 5.00 3 102), ‘‘abnor-
mality of the cerebellum’’ (HP:0001317; FDR 5.003 102),
and ‘‘truncal obesity’’ (HP:0001956; FDR 3.12 3 102)
(Table S7). The search for enrichment of OMIM terms iden-
tified Bardet-Biedl syndrome (BBS [MIM: 209900]) as the
highest hit (Fisher’s exact test: nominal p ¼ 1.2 3 104,
Bonferroni adjusted p ¼ 4.32 3 103 [EnrichR OMIM
gene set] and nominal p ¼ 2.52 3 106, Bonferroni
adjusted p ¼ 4.69 3 104 [EnrichR expanded OMIM
gene-set]). For accuracy and because some tools were not
recently updated (e.g., DAVID), we manually compiled a
curated list of genes associated with the overlapping BBS,
Joubert (JBTS [MIM: 213300]), and Meckel-Gruber (MIM:
249000) syndromes and identified a significant enrich-
ment of known BBS genes (6 genes out of 16 tested, OR
[95% CI] ¼ 5.18 [1.54–15.76], p ¼ 4.0 3 103, Bonferroni
adjusted p ¼ 0.012), JBTS genes (5/16, OR [95% CI] ¼
3.92 [1.07–11.26], p ¼ 2.0 3 102, Bonferroni adjusted
p ¼ 0.06), and BBS and JBTS genes together (10/30, OR
[95% CI] ¼ 4.33 [1.80–9.71], p ¼ 6.2 3 104, Bonferroni
adjusted p ¼ 0.0019) (Tables S8 and S9). These syndromes
are associated with abnormal structures or functions of the
primary cilium, an essential component required to sense
the environment in signal transduction.44,45 The 1,188
DE genes are also significantly enriched for genes included
in SFARI Gene, an annotated list of genes enriched in
autism genes (47 DE genes among 313 SFARI genes with
detectable expression; Fisher test, OR [95% CI] ¼ 1.63
[1.16–2.25], p ¼ 3.8 3 103; Bonferroni adjusted p ¼
0.011). We found no enrichment for genes associated
with SCZ or GWAS hits for BMI (body mass index) (Table
S10; Material and Methods). Taken together our data sug-
gest (1) that the profiling of LCL, a non-neural tissue, can
identify pathways relevant for ASD and head size and (2)
that other genes in our DE list could be relevant to brain
pathophysiologies.
We complemented our approach with unsupervised as-
sessments via Weighted Gene Co-expression Network
Analysis (WGCNA)34,46 and identified five modules for
which expression correlated with the number of CNV
copies (Figure S2; Tables S11 and S12). The ‘‘light green’’
module (51 genes, Pearson 0.95, BH FDR adjusted p ¼
28.0 3 1049) was anticorrelated with weight (p ¼ 6.0 3
104), BMI (p ¼ 3.0 3 107), and HC (p ¼ 6.0 3 105; all
FDR adjusted) and included all 22 imbalanced 16p11.2
genes expressed in LCLs, confirming the association of
16p11.2 genes with mirror effects on body weight and
HC6,7 and providing additional confidence for the speci-
ficity of our data. The second most correlated module
(264 genes, Pearson0.65, FDR adjusted p¼ 53 1012) re-
grouped genes involved in RNA biosynthesis/regulation
(GO enrichment p ¼ 4.3 3 106), gene expression/tran-
scription (p ¼ 1.7 3 105), and cilium morphogenesis
(p¼ 1.33 102). This ‘‘black’’ module correlated positively
with BMI (0.41, FDR adjusted p ¼ 4.03 104) and HC (0.3,
FDR adjusted p ¼ 3.0 3 102), supporting the association
between changes in the expression of ciliopathy genes
and these anthropometric features. Correction for gender,
age, and kinship had no substantial influence on defini-
tion of these modules and their correlations (Material
and Methods).
Our results are further supported by our recent observa-
tion that genes with modified chromosomal contacts to
BP4-BP5 600 kb 16p11.2 interval genes in CNV carriers
cell lines are also enriched (OR ¼ 1.5, p ¼ 0.030) for ciliary
genes listed in van Dam et al.47 and for genes associated
with specific ciliopathies (A.R., unpublished data). These
findings and some commonalities between the pheno-
types of BBS and 16p11.2 CNV carriers (see below) promp-
ted us to further explore the possibility of a potential
contributory role for ciliary dysfunction to aspects of the
16p11.2 pathology. Cognizant of the potential pitfalls of
drawing conclusions from LCLs, we profiled the transcrip-
tome of cortical tissues of mouse models engineered to
carry one or three copies of the 16p11.2 orthologous
region36 (n ¼ 16, i.e., 4 deletion, 4 duplication, and
8 wild-type mice, fully balanced for gender) by RNA
sequencing.35 Using generalized linear models to contrast
wild-type expression against the abnormal copy states,
we found marked overlap with human LCL findings. Of
the 311 SFARI genes (excluding KCTD13 and MVP that
map within the 16p11.2 CNV region), 299 were quantified
in mouse cortex, in particular all 45 human LCL DE genes.
Of those 45 genes, we observed differential expression
(p < 0.05) of 13 genes in mouse cortex deletion data
alone (where both studies are best powered; Fisher’s exact
test for enrichment against all genes differentially ex-
pressed in the mouse cortex, p ¼ 0.011) and of 14 genes
in the deletion and duplication combined data (p ¼
0.092). These genes include CEP290 (MIM: 610142),
YTHDC2, TOP1 (MIM: 126420), UBE3A (MIM: 601623),
RB1CC1 (MIM: 606837), GNAS (MIM: 139320), TBL1XR1
(MIM: 608628), DCUN1D1 (MIM: 605905), ARID1B (MIM:
614556), BCL2 (MIM: 151430), ROBO1 (MIM: 602430),
EPC2 (MIM: 611000), CYFIP1 (MIM: 606322), and SNX19.
At a differential expression threshold of p < 0.10, we
observed 17 of 45 LCL DE genes in the deletion data
alone (p ¼ 0.019), and 20/45 in the deletion and duplica-
tion combined data (p ¼ 0.099). These findings include
the previously described genes along with BBS4 (MIM:
600374), RORA (MIM: 600825), SNRPN (MIM: 182279),
CD44 (MIM: 107269), AFF4 (MIM: 604417), and EIF4E
(MIM: 133440). In particular, we observed a significant
enrichment of perturbed expression of genes involved in
both JBTS (p ¼ 2.6 3 104 and 2.9 3 103) and BBS (p ¼
1.4 3 103 and 1.4 3 102, in deletion and duplication
models, respectively). Cep290 expression was increased in
deletion (p ¼ 8.0 3 103) and decreased in duplication
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(p ¼ 8.0 3 102) animals. WGCNA of murine cortex RNA-
seq data further uncovered that the 149 genes-strong
module that includes the 16p11.2 interval orthologous
genes was enriched for genes involved in flagellar function
A C
B D
E G
F H
I
Figure 2. Ciliary Length Analyses in Hip-
pocampal Tissue from C57BL/6 and
16p11.2 dup/þ Mice
(A–H) Staining of cilia in theCA1 (A, C) and
dentate gyrus (E, G) regions of the hippo-
campus via ACIII (yellow) and counter-
stained with DAPI (blue) in C57BL/6
controls (A, E) and 16p11.2 duplication
models (C,G). CA1 (B,D) anddentate gyrus
(F, H) ciliary length analyses were per-
formed by plotting pixel information from
ACIII staining in C57BL/6 controls (A, E)
and 16p11.2 duplication models (C, G).
(I) Total ciliary length comparisons
were measured and plotted for both the
CA1 and dentate gyrus (SEM was plotted;
***p < 0.001).
(p ¼ 4.3 3 102). These results from
different tissues and species further
support the notion that 16p11.2
rearrangements alter ciliary gene
expression.
Although our expression analyses
are correlative, they are compatible
with a potential contributory role
for ciliary dysfunction to aspects of
the 16p11.2 pathology. If this is accu-
rate, we posited that (1) given that
dysfunction of several ciliopathy pro-
teins is associated with structural
ciliary defects, we should be able to
observe these and (2) if dysregulation
of ciliopathy proteins is a phenotypic
driver, then anti-regulation of these
genes should rescue aspects of the
16p11.2 pathology. Mice knocked-
out for genes that contribute loss-of-
function mutations to ciliopathy-
affected individuals show significant
defects in hippocampal primary cilia
length.48–52 Because this brain struc-
ture is relevant to ASD and SCZ53 and
shows 16p11.2 dosage-dependent vol-
ume changes,54 we asked whether
dosage-dependent ciliary phenotypes
could be observed in CA1, CA3, and
the dentate gyrus of mouse models
engineered to carry either one or
three copies of the 16p11.2 ortholo-
gous region.36 Although there was
no significant difference in animals
carrying the deletion, we found a
CA1-specific significant shortening of
neuronal cilia in theduplicationmodel (ciliamedian length
decrease from 5.9 to 3.9 mm [p< 1.03 103]; Figure 2). This
suggests that the observed transcriptional changes affect
ciliary length in discrete hippocampal regions.
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To test directly whether the transcriptional dysregula-
tion of cilia genes might be a driver of the pathology,
we turned to zebrafish. We have shown previously that
reciprocal under- and overexpression of KCTD13 induces
macro- and microcephaly with concomitant defects in
neurogenesis and bilateral symmetry of post-mitotic neu-
rons.13 This kctd13 morpholino-induced (MO) macroce-
phaly was rescued significantly by BBS7 (MIM: 607590)
mRNA (p < 1.0 3 104), whereas overexpression of BBS7
alone induced no appreciable phenotypes (Figure 3I).
Next, we tested CEP290, whose expression profile is oppo-
site to BBS7. We combined overexpression of human
KCTD13 with either cep290 MO or human CEP290 RNA
and asked whether suppression or overexpression of
CEP290might rescue head size and expression neurogene-
sis. Embryos co-injected with kctd13 MO and cep290
MO showed a normal head size, indistinguishable from
sham-injected embryos (p < 1.0 3 104; Figures 3A and
3B). To probe the cellular basis of this correction further,
we stained injected embryos with HuC/D antibody
Figure 3. Ciliopathy Gene Suppression or Overexpression Rescues the Neuroanatomical Defects Associated with KCTD13 Imbalance
(A) From top to bottom, dorsal views of representative 4.5 dpf controls, embryos injected with kctd13MO, and co-injected with kctd13
and cep290 MOs. The yellow double-head arrows mark the distance between the convex tip of the eyecups, a proxy for head size.
(B) Bar graph represents the distance between the eyecups for controls and injected embryos. SEM was plotted. Student’s t test was
performed and the corresponding p value is denoted on the bar graph.
(C–F) Representative photographs show ventral views of zebrafish embryos at 2 dpf stained with HuC/D. Embryos were binned into four
classes: normal bilateral expression (C), absence or reduced expression (D), ectopic expression (E), and unilateral expression (F).
(G) Percentage of embryos with normal bilateral HuC/D protein levels (blue) or unilateral HuC/D (red), ectopic (green), and absent/
reduced protein levels (purple) in the anterior forebrain in embryo batches injected with kctd13, cep290 MOs, and/or KCTD13,
CEP290mRNAs. HuC/D levels in the anterior forebrain of the embryo injected with the kctd13MO are considerably increased compared
to those of the control embryo. This defect was rescued significantly by co-injection of cep290 MO. Likewise, HuC/D levels in the
anterior forebrain of the embryo injected with the KCTD13 mRNA are considerably lower than those of the control embryo. This
defect was rescued significantly by co-injection of full-length human CEP290 mRNA. Although significant differences were observed
in unilateral and ectopic classes for embryos injected with CEP290 RNA and kctd13 MO compared to kctd13 morphants, the total
percentage of abnormal embryos remained the same. Chi-square test was performed and the corresponding p values are denoted on
the bar graph.
(H) Two-generation pedigree shows mother-daughter transmission of a CEP290 nonsense variant and a de novo 16p11.2 deletion
identified in the daughter. The genotypes, IQ, and ADOS diagnoses are indicated (see also Table S13).
(I) Bar graph represents the distance between the eyecups for controls and embryos injected with kctd13morpholino (MO), BBS7 RNA,
and co-injected with kctd13 MO and BBS7 RNA. SEM was plotted. Student’s t test was performed and the corresponding p value is
denoted on the bar graph.
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(a marker of early postmitotic neurons) and binned
them into four classes: bilateral, unilateral, ectopic, and
reduced/absent expression (Figures 3C–3F). At 2 days
post-fertilization (dpf), a time at which kctd13 overexpres-
sants are anatomically indistinguishable from sham-in-
jected embryos,13 we observed a loss of bilateral expression
of HuC/D expression in the forebrain (Figure 3G). Masked
qualitative scoring of embryos at 2 dpf injected with
KCTD13 RNA and CEP290 RNA showed a significant
rescue of bilateral HuC/D expression in the forebrain
(Fisher exact test p ¼ 9.0 3 105), whereas co-injection
with cep290 MO showed no difference compared to
embryos injected with KCTD13 RNA alone (p ¼ 0.24;
Figure 3G). Reciprocally, we scored embryos injected with
kctd13 MO with either human CEP290 RNA or MO
(Figure 3G). Suppression of kctd13 led to the ectopic
expression of HuC/D concomitant with an increased num-
ber of newborn neurons and macrocephaly as described.13
Injection of kctd13 MO and cep290 MO yielded a signifi-
cant rescue of bilateral expression of HuC/D, which was
no longer expressed ectopically but was instead restricted
to the forebrain, similar to HuC/D expression in controls
(chi-square test p ¼ 9.0 3 104; Figure 3G). This restricted
expression of HuC/D in the forebrain was consistent with
the normal head size of these double morphants observed
at 4.5 dpf (Figures 3A and 3B). In contrast, injection of
CEP290 RNA failed to rescue the ectopic expression
of HuC/D seen in kctd13 morphants. Taken together,
these data suggest that overexpression or suppression of
CEP290 alleviates the neuroanatomical defects observed
in the context of an over- or underexpression of the
16p11.2 CNV driver KCTD13, respectively.
Our studies predict that loss of CEP290 might have a
protective effect to the 16p11.2 pathology in humans. To
assess this, we sequenced the exomes of 307 individuals
of the Simons VIP collection carrying 16p11.2 deletion
or duplication.11 We identified a 61-month-old female
of northern European descent with a de novo 16p11.2
deletion and a maternally inherited nonsense mutation
c.5668G>T in CEP290 (GenBank: NM_025114.3), encod-
ing p.(Gly1890*) (Figure 3H). This allele, which is absent
from >8,000 control exomes, is the second most common
CEP290 mutation reported in literature. It was found in
homozygosity in one55 and in compound heterozygosity
with other deleterious CEP290 alleles in five JBTS-affected
families.56,57 This individual had normal HC and weight
(both 50th centile), tested negative for ASD (ADOSmodules
1 and 2), had no reported seizures, and had mild reduction
of IQ compared to her parents (full-scale IQ [FSIQ] 89; non-
verbal IQ 86; Table S13). These results should be compared
to the deletion phenotypes previously described.11 In brief,
16p11.2 BP4-BP5 deletions increase on average the HC
and the BMI by þ0.6 and þ0.8 SD at 5 years of age, respec-
tively (i.e., approximately one-third and 20% of deletion
carriers have HC and BMI equal or below 50th percentile,
respectively). Furthermore, the FSIQ of de novo 16p11.2
BP4-BP5 deletion carriers equals 83. Although the young
carrier identified here was screened originally by array
CGH because of concerns relating to expressive language
development, she has a verbal IQ of 93, i.e., 1 SD above
the mean of 16p11.2 deletion carriers (n¼ 42, mean verbal
IQ ¼ 74, SD ¼ 17.511). We are cautious at interpreting
data from a single young CNV carrier. Both follow up of
this individual and identification of additional cases are
required to investigate the modulation of 16p11.2-related
phenotypes by mutations affecting ciliary function; none-
theless, these observations are compatible with the in vivo
prediction that reduction of CEP290 might have an
ameliorating effect on key phenotypes associated with
the 16p11.2 deletion.
Discussion
The 16p11.2 rearrangements provide an opportunity to
investigate molecular mechanisms underlying the co-
morbidity triad of neurodevelopmental disorders, energy
imbalance, and HC alterations. Our study of 98 human
cell lines identified gene expression perturbations of devel-
opmental pathways including ciliopathy loci and ASD
genes. We are well aware of the limitations of the study
of LCLs, which might not be the best target tissue for
many genes, for instance genes whose expression speci-
ficity resides in other cell lineages. These experiments are
nevertheless worth pursuing, because pattern of expres-
sions in peripheral tissue might be used as a first-tier
biomarker, for example. Importantly, dysregulated path-
ways could be validated in an appropriate animal model.
Accordingly, we validated our transcriptome results in
the cerebral cortex of 16p11.2 mouse models. The mouse
model harboring duplication of the orthologous 7qF3
region concomitantly showed structural ciliary defects
specifically in the CA1 area of the hippocampus similar
to what was reported in the Bbs4/ animals.52 Whereas
the CA2 region is essential for social memory,58 CA1 is
associated with spatial memory,59 an endophenotype of
schizophrenia60,61 associated with the 16p11.2 duplica-
tion.8 The association between 16p11.2 600 kb BP4-BP5
rearrangements and transcript perturbations of ciliopathy
and autism spectrum disorder genes is further supported
by the results of our study of the chromatin conformation
changes induced by these CNVs. We uncovered that long-
range chromosomal contacts of genes located within the
600 kb interval are similarly enriched for genes associated
with autism (both SFARI-ASD and de novo ASD genes)
and the primary cilium, as well as for genes that are
differentially expressed in 16p11.2 CNV carrier cell lines,
suggesting that chromosomal contacts are necessary for
co-regulation (A.R., unpublished data). The primary cilium
has been the focus of intensive studies and emerging data
show that apart from specific ciliopathy syndromes, this
important developmental organelle plays a widespread
role in human genetic disease. For example, prior evidence
does exist that ciliary dysfunction might contribute to
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multiple neuropsychiatric disorders beyond the simple
correlation of clinical overlap. Suppression of candidate
genes for intellectual disability, SCZ, and ASD in cells re-
sulted in disturbed ciliogenesis in 56% of tested genes.62
Consistent with this observation, several well-established
ASD genes are directly involved in ciliary biology (e.g.,
AHI1 [MIM: 608894], DISC1 [MIM: 605210], CTNNB1
[MIM: 116806]) or their knockdowns result in cilia loss
(e.g., KATNAL2 [MIM: 614697], NRXN1 [MIM: 600565],
FOXP1 [MIM: 605515], CHD7 [MIM: 608892]).47 Our find-
ings suggest a new link between ciliopathy and ASDs.
Several bona fide ciliopathy loci have been associated
with discrete 16p11.2 CNV phenotypes.63–69 Our genetic
interaction experiment supports this notion further,
because changes in expression of either BBS7 or CEP290
modified the neurodevelopmental defects induced by
KCTD13 dosage imbalance. Although the mechanisms
of causality or rescue remain unknown, recent studies
have shown that a subset of ciliopathy proteins regulate
paracrine signals such as Wnt and Shh through the regu-
lation of proteasomal function proximal to the primary
cilium.70–72 KCTD13 is an ubiquitin ligase that targets
RhoA,73 offering a possible mechanistic link. Other
genes whose products participate in proteasomal function
have been implicated in ASDs, including CUL3 (MIM:
603136)74,75 and UBE3A.76,77 Of note, mice null for
Cep290, whose expression is anti-correlated to the BBS
genes in the context of the 16p11.2 transcriptome, have
been shown to rescue phenotypes induced by ablation
of Bbs6.78 We hypothesize that antagonistic regulation
of either broad proteasomal activity or specific protea-
some-dependent signaling pathways might underlie the
observed reciprocal rescue.
Our studies also have potential implications for the clin-
ical evaluation and management of 16p11.2 CNV carriers.
First, the dysregulation of ciliopathy genes in this CNV
predicts, beside the reported obesity, hyperphagia, poste-
rior fossa abnormalities, cognitive impairment, and social
communication deficits,11,79,80 plus additional co-morbid-
ities that include anomalies of urogenital tract, renal
dysfunction, and retinal defects. Several studies already
described renal defects and high incidence of genital mal-
formations involving Mu¨llerian ducts in 16p11.2 CNV car-
riers;11,81–84 these phenotypes warrant further attention.
Second, cataloging and interpreting deleterious variations
at ciliopathy loci and other DE genes identified in this
study might inform on the observed variability in clinical
expressivity of this CNV,6,11 which in turn might assist in
carrier management. The discovery of an individual car-
rying a de novo 16p11.2 deletion and a heterozygous
null CEP290 allele supports this idea. Finally, our data raise
the possibility that genes that are overexpressed in either
deletion or duplication carriers offer a route to therapeutic
development either through direct or indirect suppression
of their function. This approach is reminiscent of spinal
muscular atrophy, where expression studies in LCLs were
used as a screen to identify modifiers.85,86
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